<DOC>
	<DOCNO>NCT00786448</DOCNO>
	<brief_summary>- Data obtain Emselex routine treatment Overactive Bladder . The general objective evaluate product safety , compatibility , efficacy patient acceptance .</brief_summary>
	<brief_title>Post Marketing Surveillance Study Emselex After Launch Germany</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Darifenacin</mesh_term>
	<criteria>Patients treat Emselex Overactive Bladder Exclusion criterion contraindication specified German product information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Overactive Bladder</keyword>
</DOC>